Fig. 4

Survivals of patients with IPF with or without switching antifibrotic: Switched cases versus Non-Switch IPF Continued cases versus Non-Switch IPF Discontinued cases. Survival of patients with IPF with or without antifibrotic switching. Switch-IPF versus Non-switch-IPF Continued cases versus Non-switch-IPF Discontinued cases. P values were determined by the log-rank test. Cumulative survival probabilities from initiation of antifibrotic therapy were calculated. An event was defined as death from any cause and patients who were lost or still alive were censored at the last follow-up date